360 filings
Page 8 of 18
SEC STAFF
1vhcf6sty32ds4umwvk
18 Feb 20
SEC staff action: Order
12:00am
424B5
de63guhqwfj3b2m
7 Feb 20
Prospectus supplement for primary offering
5:03pm
8-K
056cl7
7 Feb 20
Miragen Announces Pricing of $15.0 Million Public Offering of Common Stock and Warrants to Purchase Common Stock
9:18am
424B5
z7mxf7cd 5pj02vhbrs
6 Feb 20
Prospectus supplement for primary offering
5:29pm
8-K
ja1zdernwoj
6 Feb 20
Miragen Announces Proposed Public Offering of Common Stock and Warrants to
4:06pm
SEC STAFF
3mr2e
6 Feb 20
SEC staff action: Order
12:00am
8-K
zn5v45k 6qt
30 Jan 20
Miragen Therapeutics Announces Positive Data for Cobomarsen In Adult T-cell Leukemia/lymphoma Patients with Residual Disease
7:01am
424B5
tfgubussw42sx3
12 Dec 19
Prospectus supplement for primary offering
4:29pm
8-K
zsv2yrltfbcbughkwtu
11 Dec 19
Miragen Announces Major Changes to Company’s Strategy
4:55pm
8-K
kvk0qkil3
7 Nov 19
Miragen Reports Third Quarter 2019 Results and Provides Corporate Update
4:05pm
D/A
d9qytp37p39qfge9
31 Oct 19
$5M in equity, sold $1.5M, 1 investor
5:12pm
8-K
9gdhxsopn3 r6hq
31 Oct 19
Entry into a Material Definitive Agreement
5:00pm
8-K
gev nc2y7
16 Oct 19
Miragen Announces New Clinical Data Showing MRG-110 Positively Impacted Tissue Repair and New Blood Vessel Growth
8:30am
8-K
kqz96
7 Aug 19
Miragen Reports Second Quarter 2019 Results; Regains Global Rights to MRG-110 and Announces Corporate Restructuring
4:00pm
8-K
3km2lvr5z
19 Jul 19
Departure of Directors or Certain Officers
8:01am
SEC STAFF
9naptobuf 4cso
11 Jul 19
SEC staff action: Order
12:00am
SEC STAFF
y32t4 gkqdi1ckpcnk
3 Jul 19
SEC staff action: Order
12:00am
8-K
rkh6c
21 Jun 19
Submission of Matters to a Vote of Security Holders
12:00am